Docetaxel anhydrous
Docetaxel anhydrous Brand names, Docetaxel anhydrous Analogs
Docetaxel anhydrous Brand Names Mixture
- No information avaliable
Docetaxel anhydrous Chemical_Formula
C43H53NO14
Docetaxel anhydrous RX_link
http://www.rxlist.com/cgi/generic3/docetaxel.htm
Docetaxel anhydrous fda sheet
Docetaxel anhydrous msds (material safety sheet)
Docetaxel anhydrous Synthesis Reference
No information avaliable
Docetaxel anhydrous Molecular Weight
807.879 g/mol
Docetaxel anhydrous Melting Point
232 oC
Docetaxel anhydrous H2O Solubility
Practically insoluble (0.025 mg/L)
Docetaxel anhydrous State
Solid
Docetaxel anhydrous LogP
4.258
Docetaxel anhydrous Dosage Forms
Solution: single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL) docetaxel (anhydrous).
Docetaxel anhydrous Indication
For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Lastly, for use, in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.
Docetaxel anhydrous Pharmacology
Docetaxel is a taxoid antineoplastic agent. It promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, docetaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
Docetaxel anhydrous Absorption
No information avaliable
Docetaxel anhydrous side effects and Toxicity
Oral LD50 in rat is >2000 mg/kg. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. In two reports of overdose, one patient received 150 mg/m2 and the other received 200 mg/m2 as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.
Docetaxel anhydrous Patient Information
Docetaxel anhydrous Organisms Affected
Humans and other mammals
